An important therapeutic possibility exists in that mTOR inhibitors reduce VEGF mRNA stability, thus, providing a reasonable basis to investigate whether combination therapy of mTOR inhibitors and anti VEGF agents can produce additive or synergistic beneficial results in regulating the angiogenic component of diabetic retinopathy. Combination Erlotinib price of mTOR inhibition with VEGF antagonism has demonstrated an effect in suppressing endothelial cell growth in prostate tumor cells and angiogenesis in amodel of oxygen-induced retinopathy. Dual mTOR inhibitors effective at synergizing with anti-vegf therapeutics that either inhibit a definite regulatory site on the same pathway or inhibit a parallel prosurvival pathway would supply a wider mechanistic treatment of the angiogenic process. Because mTOR inhibitors have a primary anti angiogenic impact, mediated via modulation of HIF 1, it may be possible to approach anti angiogenic remedy from a dual approach in combination with anti VEGF monoclonal Lymph node antibodies or VEGF trap while reducing the potential for overlapping toxicities and at the same time selectively targeting the operant mechanism in the pathobiology of diabetic retinopathy. A few Phase I studies have examined the safety profile of combination therapy using mTOR and bevacizumab inhibitors sirolimus, everolimus, or the twin mTOR inhibitor WYE 125132 in cancer patients. Preliminary data suggest that combination therapy of those agents can be a possible therapeutic modality with tolerable unwanted effects. Generally, the intensity and occurrence of observed toxicities with mix of these drugs were no more than what has been observed and associated with every individual HDAC6 inhibitor drug. Of therapeutic advantage was the potential to reduce the dose of every individual agent to improve dose limiting toxicities over the long run while preserving or even increasing efficacy of treatment. Future tests will need to elucidate whether combination therapy versus successive drug treatment routine may also offer an alternative attractive treatment alternative for disease management. An analogous approach could be taken by connecting mTOR inhibitors with other antagonists or brokers where the mechanism of action targets an alternate path, thereby boosting the possibility of additive or synergistic effects on measures. The combinatorial drug approach with mTOR inhibitors could be extended to be coadministered with an entire class of anti-inflammatory agents as combination therapy. The mTOR inhibitors in combination with Nepafenac, currently in clinical trials for non proliferative diabetic retinopathy and macular edema, would appear to become a combinatorial drug method of combat diabetic retinopathy. Fresh studies using external 0.